Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial

Fig. 2

Kaplan-Meier curves for overall survival (a, c, and e) and progression-free survival (b, d, and f) estimation in both groups in all patients (a, b) and in cases with BCLC B (c, d), and BCLC C (e, f) lesions. Median (95%CI). DEB-TACE Drug-eluting bead transarterial chemoembolization, D + apatinib, DEB-TACE plus apatinib, BCLC Barcelona clinic liver cancer, P value for the log-rank test

Back to article page